Why do patients with schizophrenia smoke?

被引:190
作者
Winterer, Georg [1 ]
机构
[1] Univ Dusseldorf, Dept Psychiat, D-40629 Dusseldorf, Germany
关键词
nicotine; schizophrenia; self-medication; smoking; NICOTINIC ACETYLCHOLINE-RECEPTORS; PURSUIT EYE-MOVEMENTS; REACTION-TIME-TASK; CIGARETTE-SMOKING; SMOOTH-PURSUIT; HUMAN-BRAIN; SUSTAINED ATTENTION; PREFRONTAL CORTEX; NEGATIVE SYMPTOMS; TOBACCO SMOKING;
D O I
10.1097/YCO.0b013e3283366643
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose of review Among the mentally ill, smoking prevalence is highest in patients with schizophrenia (similar to 70-80%). This can impose a significant financial burden on patients, not to speak of increased smoking-related morbidity and mortality. Therefore, it is critical for clinicians to understand why patients with schizophrenia smoke in order to adapt treatment schemes. Understanding the reasons may also help to develop new drugs that target the nicotinic system in the brain as well as smoking cessation programs that are specifically designed for this particular patient population. Recent findings So far, several reasons have been identified which are believed to explain tobacco consumption in patients with schizophrenia. Originally, it was widely believed that patients with schizophrenia smoke to increase hepatic clearance and to restore the dopamine blockade of certain antipsychotic drugs to diminish their side effects. However, more recently it became obvious that cigarette smoking may also be reinforcing for patients because it improves psychiatric symptoms, most notably negative and cognitive symptoms. The underlying molecular mechanisms of these nicotine effects are currently under intensive investigation. Summary Heavy smoking in schizophrenia cannot simply be viewed as a 'bad habit'. Rather, self-medication of clinical symptoms and side effects of antipsychotic drugs appear to play a major role.
引用
收藏
页码:112 / 119
页数:8
相关论文
共 105 条
[21]   Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia [J].
de Haan, L ;
Booij, J ;
Lavalaye, J ;
van Amelsvoort, T ;
Linszen, D .
PSYCHOPHARMACOLOGY, 2006, 183 (04) :500-505
[22]  
DELEON J, 1995, AM J PSYCHIAT, V152, P453
[23]   Clinical pharmacokinetics of quetiapine - An atypical antipsychotic [J].
DeVane, CL ;
Nemeroff, CB .
CLINICAL PHARMACOKINETICS, 2001, 40 (07) :509-522
[24]   EVIDENCE OF MORE RAPID STIMULUS EVALUATION FOLLOWING CIGARETTE-SMOKING [J].
EDWARDS, JA ;
WESNES, K ;
WARBURTON, DM ;
GALE, A .
ADDICTIVE BEHAVIORS, 1985, 10 (02) :113-126
[25]  
Eissenberg T, 1996, PSYCHOPHARMACOLOGY, V127, P328, DOI 10.1007/BF02806011
[26]   Behavioral and neural consequences of prenatal exposure to nicotine [J].
Ernst, M ;
Moolchan, ET ;
Robinson, ML .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2001, 40 (06) :630-641
[27]   Effect of nicotine on brain activation during performance of a working memory task [J].
Ernst, M ;
Matochik, JA ;
Heishman, SJ ;
Van Horn, JD ;
Jons, PH ;
Henningfield, JE ;
London, ED .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (08) :4728-4733
[28]   Smoking history and nicotine effects on cognitive performance [J].
Ernst, M ;
Heishman, SJ ;
Spurgeon, L ;
London, ED .
NEUROPSYCHOPHARMACOLOGY, 2001, 25 (03) :313-319
[29]   A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in schizophrenia families [J].
Faraone, SV ;
Su, J ;
Taylor, L ;
Wilcox, M .
HUMAN HEREDITY, 2004, 57 (02) :59-68
[30]   Neuroprotective and Neurotoxic Effects of Nicotine [J].
Ferrea, S. ;
Winterer, G. .
PHARMACOPSYCHIATRY, 2009, 42 (06) :255-265